Tarsus Pharmaceuticals, Inc. (TARS) Tops Q3 EPS by 33c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($0.61), $0.33 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $48.1 million versus the consensus estimate of $43.18 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Micron Technology (MU) call put ratio 1.3 calls to 1 put as share price down 1%
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue